TRIM5alpha-mediated block of HIV-1 production

  • Ikeda, Yasuhiro H (PI)

Project: Research project

Project Details

Description

Human immunodeficiency virus type 1 (HIV-1) is the major cause of acquired immunodeficiency syndrome in
humans. Rhesus monkey TRIM5alpha (rhTRIM5a) is a potent intrinsic anti-retroviral factor which targets
incoming HIV-1 capsid and promotes its premature disassembly. rhTRIM5a comprises an RBCC domain and a
B30.2(SPRY) domain, and sequences in the B30.2(SPRY) domain dictate the potency and specificity of the
restriction. Since rhTRIM5a recognizes proteolytically processed capsids in incoming virions, it was believed
that rhTRIM5a blocks only the early phase of the HIV-1 life cycle. Contrary to this general consensus, we have
recently discovered that rhTRIM5a, but not its human orthologue (huTRIM5a), potently blocks HIV-1 production
by reducing the levels of Gag proteins in producer cells. Unexpectedly, the rhTRIM5a RBCC domain, but not
the B30.2(SPRY) domain, plays a pivotal role in the block of HIV-1 production. Moreover, when HIV-1 Gag is
over-expressed, encapsidation of rhTRIM5a is observed in viral-like particles made with HIV-1 Gag
polyproteins, suggesting the interaction between rhTRIM5a and HIV-1 Gag polyprotein during viral production.
Our long-term goal is to develop novel intervention strategies to block HIV-1 replication based on
understanding of anti-HIV-1 activities of host restriction factors. The overall goal of this application is to
understand the underlying molecular mechanisms of the rhTRIM5a-mediated block of HIV-1 production; a clear
understanding is essential for any rational attempt to block virus production by small molecules.
Our central hypothesis is that rhTRIM5a interacts with HIV-1 Gag polyprotein before viral assembly and
promotes rapid degradation of Gag, thereby blocking HIV-1 production. Specific aims are; 1) to characterize
the nature and biological relevance of the rhTRIM5a-mediated block on lenti/retroviral production, 2) to
determine the essential biological properties of rhTRIM5a for the block of HIV-1 production, and 3) to
determine how rhTRIM5a reduces the levels of HIV-1 Gag in the producer cells. Accomplishing the specific
aims outlined in this proposal should lead to considerable insights into how rhTRIM5a blocks HIV-1 production
and it will also reveal potential targets for HIV-1 therapy. For instance, it may be possible to develop molecular
strategies which transform huTRIM5a into an effective inhibitor of HIV-1 production.
StatusFinished
Effective start/end date9/15/088/31/10

Funding

  • National Institutes of Health: $339,975.00

ASJC

  • Medicine(all)
  • Immunology and Microbiology(all)

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.